Clinical trial
A Phase 2, 14-week Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Multisite Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
NCT05472090 is registered in ClinicalTrials.gov with Tonix Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, 14-week Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Multisite Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
- Lead sponsor
- Tonix Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 18, 2022
- Completion date
- July 27, 2023
- Enrollment
- 63 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.
covid-19, long covid, long haul covid, post-acute sequelae of sars-cov-2 (pasc) infection